The U.S. Food and Drug Administration (USFDA) has inspected Hikal’s pharmaceutical manufacturing facility located at Panoli, Gujarat. The five-day detailed preapproval inspection of an API during the period May 8, 2023-May 12, 2023 was concluded with 'Zero 483 observations’ from the USFDA Agency. This latest audit re-emphasizes the company’s commitment towards maintaining the best in class quality, compliance and regulatory standards across its manufacturing sites.
Hikal is a leading manufacturer and supplier of API's and intermediates globally.
